Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
81
-
Total 13F shares, excl. options
-
12.5M
-
Shares change
-
+2.43M
-
Total reported value, excl. options
-
$293M
-
Value change
-
+$61.8M
-
Put/Call ratio
-
0.43
-
Number of buys
-
54
-
Number of sells
-
-25
-
Price
-
$23.48
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2017
101 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2017.
CRISPR Therapeutics AG - Common Stock (CRSP) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.5M shares
of 86M outstanding shares and own 14.54% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (3.22M shares), Abingworth LLP (1.95M shares), CLOUGH CAPITAL PARTNERS L P (891K shares), FARALLON CAPITAL MANAGEMENT LLC (859K shares), FRANKLIN RESOURCES INC (795K shares), Global Thematic Partners, LLC (633K shares), BlackRock Inc. (553K shares), New Leaf Venture Partners, L.L.C. (508K shares), CREDIT SUISSE AG/ (443K shares), and Opaleye Management Inc. (281K shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.